Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for DGWPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 -2.309M
March 31, 2026 72.54M
December 31, 2025 169.12M
September 30, 2025 88.05M
June 30, 2025 -38.63M
March 31, 2025 58.85M
December 31, 2024 115.58M
September 30, 2024 68.92M
June 30, 2024 -42.01M
March 31, 2024 36.40M
December 31, 2023 153.67M
September 30, 2023 58.86M
June 30, 2023 -3.365M
March 31, 2023 -4.541M
December 31, 2022 137.46M
September 30, 2022 -64.58M
June 30, 2022 -202.07M
March 31, 2022 -28.00M
December 31, 2021 135.36M
September 30, 2021 110.99M
June 30, 2021 116.01M
March 31, 2021 91.63M
December 31, 2020 436.67M
September 30, 2020 69.92M
June 30, 2020 -17.08M
Date Value
March 31, 2020 54.41M
December 31, 2019 96.29M
September 30, 2019 51.30M
June 30, 2019 8.981M
March 31, 2019 26.47M
December 31, 2018 52.57M
September 30, 2018 28.78M
June 30, 2018 -49.78M
March 31, 2018 -30.63M
December 31, 2017 76.35M
September 30, 2017 55.52M
June 30, 2017 3.761M
March 31, 2017 29.64M
December 31, 2016 112.54M
September 30, 2016 53.57M
June 30, 2016 36.10M
March 31, 2016 11.48M
December 31, 2015 51.51M
September 30, 2015 65.85M
June 30, 2015 -4.304M
March 31, 2015 -70.33M
December 31, 2014 146.09M
September 30, 2014 59.02M
June 30, 2014 1.872M
March 31, 2014 34.41M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ottobock SE & Co. KGaA 53.52M
Abbott Laboratories 2.488B
AngioDynamics, Inc. 17.45M
Alphatec Holdings, Inc. 20.51M
AtriCure, Inc. 22.19M